China maintains focus on APIs with new guidance
China’s antitrust authority has indicated that enforcement against active pharmaceutical ingredient suppliers will remain a priority after releasing sector-specific guidance for only the second time in its history.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.